Maybe I should know these numbers but I don't so please help educate us. What is the percent difference that makes a significant symmetry break? What percentage of the time does a symmetry break like this on the downside lead to a higher low?

Does anyone have any experience with the Beacon Learning group for trade mentoring? Looking for someone to help me round out my trading

Don't know about the need for a new ED drug but the big move in the stock came last February on the advisory board recommendation to approve their obesity drug. The FDA was to have come to a decision April 17 but they extended their time to July 17.

It will be the approval or disapproval of that application that is likely to be a big mover for the stock

interesting data.

If it isn't proprietary-do you have the sell set up the same way as you do for the SPY system

In other words, a buy signal triggers an EOD buy on the SPY and a subsequent sell triggers a market on open sell.

Did you run your statistics using similar rules for the /ES?

interesting observation. Will you be posting that trigger level when you see it during the day?

I don't think you should put pending trades in a table. Your communication includes an e-mail, SMS text if you sign up for it, and the current trade tab.

Buy if SPY closes < XXX.XX is clear enough.

Kids are a joy to have. Surely someone has already told you to say goodbye to life as you know it now. Children will transform everything.

ARNA is scheduled for an FDA decision by Oct 22 on Lorcaserin, their obesity drug. The history of the FDA and obesity drugs isn't great and there are lots of reasons to be pessimistic about their approval of lorcaserin. The FDA can act before Oct 22 or they can ask for more data and delay. If they approve it the stock will soar but I wouldn't put all my retirement money on it.

AMLN goes to the FDA 10/22 for approval of their new diabetes treatment. Would seem that any significant action would occur at that date but it's an interesting stock to keep on the list. Always hard to predict what the FDA will do but approval seems likely for this one.

Of course with a biopharmaceutical it is very dependent on it's drug development milestones. It jumped up in the spring on news of their colorectal registration trial of perifosine and then on news that they were accepted for abstract presentation as ASCO. It has drifted down since then. It might be a good long term play but these companies can drift for months until they complete trials, present abstracts, or get FDA review.

It isn't how it closes but how it opens that sets the settlement price for the index options. At least that's how I understand it.

Of course Dr O knows about irreversible shock. Leave them bleeding and in shock too long-game over

This is twice now. I open up a link from the site and I get a warning from McAfee that it is an "attack" site.

This time it happened from this post